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Psychotic symptoms, including hallucinations, delusions,
delirium, sleep disturbances, are a common problem
associated with movement disorders. For instance, psy-
chosis as one of the most disabling levodopa-induced
complication occurs in up to 30% of patients with Parkin-
son's disease (PD). The prevalence of psychotic symptoms
in Huntington's disease (HD) ranges from 3.4–30%,
while only schizophrenia-like expression was noted in 9%
of HD patients. Psychosis can be more disabling than the
motor symptoms in patients with movement disorders: it
seriously influence the patient's ability to maintain inde-
pendence and is among the greatest risk factors for nurs-
ing home placement. The conventional antipsychotics are
poorly tolerated in patients with movement disorders,
and in particular in PD patients, since they can induce
profound worsening or appearance of parkinsonism and
tardive symptoms. The atypical antipsychotic drugs (ie,
clozapine, olanzapine, quetiapine, risperidone, etc.) offer
improved therapeutic strategy that control psychotic
symptoms without compromising motor function
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